|
Synonyms: LY-2439821 | LY2439821 | Taltz®
ixekizumab is an approved drug (FDA & EMA (2016))
Compound class:
Antibody
Comment: Ixekizumab binds to IL-17A and blocks its action.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. A protein BLAST search using the variable region of the heavy chain of ixekizumab identifies this as sequence 118 from patent US7838638 [1]. In this patent binding affinity data for human IL-17 is provided for several antibody clones, but it does not specify which was chosen as ixekizumab, although mAbs 126, 121 and 104 did undergo additional experimental investigations. |
| No information available. |
Summary of Clinical Use  |
| Ixekizumab is approved for the treatment of psoriasis. Positive results from a Phase 2 study are reported in [6], and Phase 3 results are reviewed in [5]. In March 2016, the US FDA approved ixekizumab for the treatment of moderate-to-severe plaque psoriasis. The EMA granted marketing authorisation in April 2016. Phase 3 results following 60 weeks of treatment are reported in [8], showing longer term efficacy (with ~80% of patients seeing at least a 75% improvement in their skin symptoms at 60 weeks). |
| Mechanism Of Action and Pharmacodynamic Effects |
| The IL-17 pathway is an established driver of psoriasis pathogenesis [7,9]. Ixekizumab effectively neutralises circulating IL-17A and reduces IL-17-induced pro-inflammatory signalling. This leads to an improvement in clinical disease symptoms. . |
| External links |
|
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |
